Liver X Receptor Inverse Agonist SR9243 Suppresses Nonalcoholic Steatohepatitis Intrahepatic Inflammation and Fibrosis
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
Abnormal metabolism of cholesterol may be a contributing factor in nonalcoholic steatohepatitis (NASH) pathogenesis. Accumulating evidence has shown that liver X receptor (LXR) is closely related to intrahepatic inflammation and fibrosis. In this study, we evaluated the effects of a novel liver-specific LXR inverse agonist, SR9243, on antifibrosis in NASH mice. A high-cholesterol diet was employed to induce NASH in BALB/c mice by either carbon tetrachloride (CCL4) administration or bile-duct ligation (BDL). Once NASH was induced, mice were treated with SR9243 for one month by intraperitoneal (i.p.) injection. Liver tissues were collected to determine the degree of fibrosis and intrahepatic inflammation via pathological examination and QPCR; serum was collected to analyze the plasma lipid levels and liver function by clinical biochemistry. The mice developed hepatic steatosis, severe hepatic inflammation, and fibrosis by BDL or CCL4. Treatment with SR9243 significantly reduced the severity of hepatic inflammation and ameliorated hepatic fibrosis; simultaneously, body weight, serum glucose, and plasma lipid levels were controlled effectively. Our data demonstrate that SR9243 exerts an antifibrotic and anti-inflammatory effect in NASH mice; hence these findings highly suggest that LXR inverse agonist could be therapeutically important in NASH treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Paradoxically, the LXR inverse agonist SR9243 had similar beneficial anti-fibrotic and anti-inflammatory effects in two BASH (both-alcoholic and steatohepatitis) mouse models, which were induced by using a high-cholesterol diet in combination with either CCl 4 administration or bile-duct ligation.[167]”
From Nuclear receptors in liver fibrosis (2021) · cites this paper as [167]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Role of LXRs in control of lipogenesis
Schultz, J. R., Tu, H., Luk, A., Repa, J. J., Medina, J. C., Li, L., Schwendner, S., Wang, S., Thoolen, M., Mangelsdorf, D. J., et al. (2000) · Genes & Development · doi:10.1101/gad.850400 · Cited by 1,499
Cusi, K. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.02.003 · Cited by 911
Transcriptional integration of metabolism by the nuclear sterol-activated receptors LXR and FXR
Calkin, A. C., & Tontonoz, P. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3312 · Cited by 779 · cited 1×
“Previous studies have proved that LXRα is highly expressed in kidney, liver, intestines, and adipose tissue while LXRβ is expressed widespreadly throughout the body [8].”
Liver X receptors in lipid metabolism: opportunities for drug discovery
Hong, C., & Tontonoz, P. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4280 · Cited by 587
Tomita, K., Tamiya, G., Ando, S., Ohsumi, K., Chiyo, T., Mizutani, A., Kitamura, N., Toda, K., Kaneko, T., Horie, Y., et al. (2006) · Gut · doi:10.1136/gut.2005.071118 · Cited by 438
Yang, H., Fang, F., Chang, R., & Yang, L. (2013) · Hepatology · doi:10.1002/hep.26315 · Cited by 261
Teratani, T., Tomita, K., Suzuki, T., Oshikawa, T., Yokoyama, H., Shimamura, K., Tominaga, S., Hiroi, S., Irie, R., Okada, Y., et al. (2012) · Gastroenterology · doi:10.1053/j.gastro.2011.09.049 · Cited by 241
Targeting nuclear receptors for the treatment of fatty liver disease
Tanaka, N., Aoyama, T., Kimura, S., & Gonzalez, F. J. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.05.011 · Cited by 212
Flaveny, C. A., Griffett, K., El-Gendy, B. E.-D. M., Kazantzis, M., Sengupta, M., Amelio, A. L., Chatterjee, A., Walker, J., Solt, L. A., Kamenecka, T. M., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.05.007 · Cited by 208
Miura, K., Seki, E., Ohnishi, H., & Brenner, D. A. (2010) · Gastroenterology Research and Practice · doi:10.1155/2010/362847 · Cited by 149
Cited by
Lin, H., Liu, Z., Yang, H., Lu, L., Chen, R., Zhang, X., Zhong, Y., & Zhang, H. (2022) · Environmental Science & Technology · doi:10.1021/acs.est.2c03452 · Cited by 129
Dixon, E. D., Nardo, A. D., Claudel, T., & Trauner, M. (2021) · Genes · doi:10.3390/genes12050645 · Cited by 125
Huang, P. F., Huang, F., Liu, H.-Z., Zhang, T., Yang, M., & Sun, C. (2019) · Metabolism · doi:10.1016/j.metabol.2019.01.018 · Cited by 102
Self-citationCarpenter, K. J., Valfort, A.-C., Steinauer, N., Chatterjee, A., Abuirqeba, S., Majidi, S., Sengupta, M., Di Paolo, R. J., Shornick, L. P., Zhang, J., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-56038-1 · Cited by 65
Immunoregulation of Liver Fibrosis: New Opportunities for Antifibrotic Therapy
(2024) · doi:10.1146/annurev-pharmtox-020524-012013 · Cited by 64
Liver X receptors and liver physiology
Russo-Savage, L., & Schulman, I. G. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2021.166121 · Cited by 61
Ni, M., Zhang, B., Zhao, J., Feng, Q., Peng, J., Hu, Y., & Zhao, Y. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.108778 · Cited by 60
Screening for liver X receptor modulators: Where are we and for what use?
Buñay, J., Fouache, A., Trousson, A., de Joussineau, C., Bouchareb, E., Zhu, Z., Kocer, A., Morel, L., Baron, S., & Lobaccaro, J. A. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15286 · Cited by 48
Targeting fatty acid metabolism for fibrotic disorders
Hwang, S., & Chung, K. W. (2021) · Archives of Pharmacal Research · doi:10.1007/s12272-021-01352-4 · Cited by 50
Nuclear receptors in liver fibrosis
Königshofer, P., Brusilovskaya, K., Petrenko, O., Hofer, B. S., Schwabl, P., Trauner, M., & Reiberger, T. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2021.166235 · Cited by 45
Development of LXR inverse agonists to treat MAFLD, NASH, and other metabolic diseases
Griffett, K., & Burris, T. P. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1102469 · Cited by 42
Huang, P. F., Tu, B., Liao, H.-J., Huang, F., Li, Z., Zhu, K.-Y., Dai, F., Liu, H.-Z., Zhang, T.-Y., & Sun, C. (2021) · Scientific Reports · doi:10.1038/s41598-021-85421-0 · Cited by 38
Self-citationWu, P., Luo, X., Wu, H., Zhang, Q., Dai, Y., & Sun, M. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120311 · Cited by 37
Cell metabolism-based therapy for liver fibrosis, repair, and hepatocellular carcinoma
Gilgenkrantz, H., Paradis, V., & Lotersztajn, S. (2023) · Hepatology · doi:10.1097/hep.0000000000000479 · Cited by 37
Paraconiothins A–J: Sesquiterpenoids from the Endophytic Fungus Paraconiothyrium brasiliense ECN258
Nakashima, K., Tomida, J., Hirai, T., Kawamura, Y., & Inoue, M. (2019) · Journal of Natural Products · doi:10.1021/acs.jnatprod.9b00638 · Cited by 33
Liver X receptors agonists suppress NLRP3 inflammasome activation
Yu, S.-X., Chen, W., Hu, X.-Z., Feng, S., Li, K.-Y., Qi, S., Lei, Q.-Q., Hu, G., Li, N., Zhou, F., et al. (2016) · Cytokine · doi:10.1016/j.cyto.2016.12.003 · Cited by 31
Zheng, D.-C., Hu, J.-Q., Mai, C.-T., Huang, L., Zhou, H., Yu, L., & Xie, Y. (2024) · Acta Pharmacologica Sinica · doi:10.1038/s41401-024-01315-7 · Cited by 30
MicroRNA-15a-5p Regulates the Development of Osteoarthritis by Targeting PTHrP in Chondrocytes
Duan, Z., Huang, P. F., Tu, C., Liu, Q., Li, S., Long, Z., & Li, Z. (2019) · BioMed Research International · doi:10.1155/2019/3904923 · Cited by 29
Self-citationDiscovery of novel liver X receptor inverse agonists as lipogenesis inhibitors
Chen, Z., Chen, H., Zhang, Z., Ding, P., Yan, X., Li, Y., Zhang, S., Gu, Q., Zhou, H., & Xu, J. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112793 · Cited by 28
Self-citationPathogenesis and Therapeutic Strategies Related to Non-Alcoholic Fatty Liver Disease
Teng, T., Qiu, S., Zhao, Y., Zhao, S., Sun, D., Hou, L., Li, Y., Zhou, K., Yu, X., Yang, C., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23147841 · Cited by 27
Lockhart, S. M., Mušo, M., Zvetkova, I., Lam, B., Ferrari, A., Schoenmakers, E., Duckett, K., Leslie, J., Collins, A., Romartínez-Alonso, B., et al. (2024) · Nature Metabolism · doi:10.1038/s42255-024-01126-4 · Cited by 24
Self-citationHu, S., Ai, Y., Hu, C., Bawa, F. N. C., & Xu, Y. (2024) · Genes & Diseases · doi:10.1016/j.gendis.2024.101372 · Cited by 23
Clark, A. T., Russo-Savage, L., Ashton, L. A., Haghshenas, N., Amselle, N. A., & Schulman, I. G. (2025) · Nature Communications · doi:10.1038/s41467-025-56565-8 · Cited by 21
New Horizons for the Roles and Association of APE1/Ref-1 and ABCA1 in Atherosclerosis
Chen, W., Wang, S., & Xing, D. (2021) · Journal of Inflammation Research · doi:10.2147/jir.s330147 · Cited by 20
Antihyperlipidemic Activity of Gut-Restricted LXR Inverse Agonists
Griffett, K., Hayes, M. E., Bedia‐Diaz, G., Appourchaux, K., Sanders, R. K., Boeckman, M. P., Koelblen, T., Zhang, J., Schulman, I. G., Elgendy, B., et al. (2022) · ACS Chemical Biology · doi:10.1021/acschembio.2c00057 · Cited by 16
Fernández‐Martínez, E., Rodríguez-Pastén, A., Pérez‐Hernández, N., Soria-Jasso, L. E., & Cariño‐Cortés, R. (2022) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201023666220818145350 · Cited by 15
Qin, X., Hu, D., Li, Q., Zhang, S., Qin, Z., Wang, L., Liao, R. J., Wu, Z., & Liu, Y. (2025) · Molecular Medicine · doi:10.1186/s10020-025-01153-1 · Cited by 12
Mai, C.-T., Zheng, D.-C., Li, X., Zhou, H., & Xie, Y. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105747 · Cited by 10
Liu, A., Yu, H., Yang, Y., Xue, F.-Y., Chen, X., Zhang, Y., Zhou, Z.-Y., Zhang, B., Li, L., Sun, C., et al. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s231125 · Cited by 9
Self-citationHan, W., Zhang, D., Zhang, P., Tao, Q., Du, X., Yu, C., Dong, P., & Zhu, Y. (2023) · BMC Complementary Medicine and Therapies · doi:10.1186/s12906-023-04253-9 · Cited by 7
The gene regulatory networks shaping macrophage plasticity and altered function in fibrosis
Kolostyák, Z., & Nagy, L. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1767954 · Cited by 6
Cholestenoic acid analogues as inverse agonists of the liver X receptors
Álvarez, L. D., Dansey, M. V., Ogara, M. F., Peña, C. I., Houtman, R., Veleiro, A. S., Pecci, A., & Burton, G. (2020) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2020.105585 · Cited by 6
Nuclear Receptors in Energy Metabolism
Walth-Hummel, A. A., Herzig, S., & Rohm, M. (2022) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-11836-4_4 · Cited by 5
Arifuzzaman, S., Labu, Z. K., Harun‐Or‐Rashid, M., Laboni, F. R., Khatun, M. R., Ali, M. S., Hossain, S., & Chowdhury, N. S. (2024) · Biomedical & Pharmacology Journal · doi:10.13005/bpj/2960 · Cited by 3
Nuclear receptors as therapeutic targets in metabolic and cardiovascular disorders
Li, F., Chen, Q., Dai, Y., & Lu, L. (2025) · iScience · doi:10.1016/j.isci.2025.114042 · Cited by 1
Gu, C. Y., Yan, L. S., Cheng, L., Huang, Z. S., Li, J. J., Liu, W. L., Tan, Q. L., Zhang, H., & Zhang, Y. (2026) · International Immunopharmacology · doi:10.1016/j.intimp.2025.116105 · Cited by 1
Liver X Receptors in the Cardiovascular System
Bal, N. B., Uludağ, M. O., & Demirel-Yılmaz, E. (2019) · Turkiye Klinikleri Journal of Medical Sciences · doi:10.5336/medsci.2019-70199
Tu, B., Duan, S., Wu, M. Y., Wei, B., & Huang, P. F. (2022) · Research Square · doi:10.21203/rs.3.rs-2031871/v1
Self-citationTranscription factors in abnormal metabolism and inflammatory of NAFLD
Ni, Y. (2023) · Open Journal of Clinical and Medical Images · doi:10.52768/2833-2725/1093
(2024) · Frontiers research topics · doi:10.3389/978-2-8325-4473-0
Arifuzzaman, S., Harun‐Or‐Rashid, M., Laboni, F. R., Khatun, M. R., & Chowdhury, N. S. (2025) · Computational Toxicology · doi:10.1016/j.comtox.2025.100361
Lockhart, S. M., Mušo, M., Zvetkova, I., Lam, B., Ferrari, A., Schoenmakers, E., Duckett, K., Leslie, J., Romartínez-Alonso, B., Tadross, J. A., et al. (2024) · Research Portal (Queen's University Belfast)
Rôle des récepteurs aux oxystérols dans la physiopathologie ovarienne
Dallel, S. (2023) · theses.fr (ABES) · doi:10.70675/afdacd33z9d4az4e3az9a00zd0f5b194e82e
Cheng, Y., Wu, Z., Huang, R., Li, Q., Yan, D., Chen, Y., Zhu, W.-F., & Li, F. (2026) · Gut Microbes · doi:10.1080/19490976.2026.2701349
Melnikova, I., Karabanovich, G., Dušek, J., Ambrož, M., Laštůvková, H., Smutný, T., Bajnokova, M., Kamaraj, R., Salam, R., Reguli, A., et al. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.119458
Liver X receptor (LXR) signalling in macrophage inflammation and cardiometabolic disease
Zijlstra, L. F., de Winther, M. P. J., Kooijman, S., Castrillo, A., & Neele, A. E. (2026) · Cardiovascular Research · doi:10.1093/cvr/cvag214
BindingDB (2022) · UC San Diego · doi:10.7270/q2rb78bb
Metadata
- Authors
- Huang, P., Kaluba, B., Jiang, X.-L., Chang, S., Tang, X.-F., Mao, L.-F., Zhang, Z.-P., & Huang, F.-Z.
- Affiliations
- Central South University (CN)
- Yangtze University (CN)
- Department of General Surgery, Xiangya Hospital, Central South University, No. 87 Xiangya Road, Changsha 410008, China
- Department of General Surgery, The Third Xiangya Hospital, Central South University, No. 138 Tongzipo Road, Changsha 410013, China
- Venue
- BioMed Research International
- Publisher
- Wiley
- Published
- 2018
- Volume
- 2018
- Pages
- 1-7
- ISSN
- 1110-7243 (ISSN-L)
- 2314-6133
- 2314-6141
- PMC
- PMC5835296
- OpenAlex
- W2789257932
- Cited by
- 44
- References
- 26
- Citations by year
- 2026: 5 · 2025: 4 · 2024: 6 · 2023: 4 · 2022: 6 · 2021: 7 · 2020: 4 · 2019: 7
- FWCI
- 3.51
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- BioMed Research International (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Hunan Provincial Innovation Foundation for Postgraduate (CX2017B073)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- liver X receptor, nonalcoholic steatohepatitis, liver fibrosis, intrahepatic inflammation, cholesterol metabolism, bile duct ligation, carbon tetrachloride, high-cholesterol diet, hepatic steatosis, plasma lipid levels, antifibrotic therapy
- MeSH terms
- Liver X Receptors, Animals, Bile Ducts, Blood Glucose, Body Weight, Carbon Tetrachloride, Inflammation, Insulin, Ligation, Lipids, Liver, Liver Cirrhosis, Male, Mice, Inbred BALB C, RNA, Messenger, Sulfonamides, Cytokines, Inflammation Mediators, Hepatocytes, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.